{"commentary":{"count":7,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":7},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"NCT04956640","nct_id":"NCT04956640","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04956640. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"LY3537982 administered orally.","label":"LY3537982 (Dose Escalation)","type":"EXPERIMENTAL"},{"description":"LY3537982 administered orally either alone or with another investigational agent.","label":"LY3537982 (Dose Expansion)","type":"EXPERIMENTAL"},{"description":"LY3537982 administered orally either alone or with another investigational agent","label":"LY3537982 (Dose Optimization)","type":"EXPERIMENTAL"}],"collaborators":["Merck Sharp & Dohme LLC"],"completion_date":{"date":"2027-04","type":"ESTIMATED"},"conditions":["Carcinoma, Non-Small-Cell Lung","Colorectal Neoplasms","Endometrial Neoplasms","Ovarian Neoplasms","Pancreatic Neoplasms","Biliary Tract Neoplasms"],"enrollment":{"count":540,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"LY3537982","type":"DRUG"},{"name":"Pembrolizumab","type":"DRUG"},{"name":"Cetuximab","type":"DRUG"},{"name":"Pemetrexed","type":"DRUG"},{"name":"Cisplatin","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"}],"last_update":"2026-05-29","lead_sponsor":"Eli Lilly and Company","official_title":"A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2027-04","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY3537982 monotherapy","timeFrame":"Cycle 1 (21 Days)"},{"measure":"Phase 1b: To assess the safety and tolerability of LY3537982 when administered alone or in combination with other investigational agents","timeFrame":"Cycle 1 (21 Days)"},{"measure":"Phase 1b: To determine the optimal dose of LY3537982 to be administered to treatment-naïve participants with advanced NSCLC in combination with pembrolizumab","timeFrame":"Estimated up to 2 years"},{"measure":"To determine the optimal dose of LY3537982 to be administered to participants who have received at least one prior oxaliplatin- or irinotecan-containing regimen for advanced or metastatic CRC in combination with cetuximab","timeFrame":"Estimated up to 2 years"},{"measure":"To assess the antitumor activity of LY3537982 monotherapy in participants with advanced pancreatic cancer with KRAS G12C mutation","timeFrame":"Estimated up to 2 years"}],"references":[],"start_date":{"date":"2021-07-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)","url":"https://clinicaltrials.gov/study/NCT04956640"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04956640"}